Alliance Global Partners Trims OpGen (NASDAQ:OPGN) Target Price to $3.00

OpGen (NASDAQ:OPGN) had its price target cut by Alliance Global Partners from $4.35 to $3.00 in a report released on Wednesday, The Fly reports.

Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and set a $4.00 target price on shares of OpGen in a research note on Wednesday, December 15th. UBS Group started coverage on OpGen in a research note on Thursday, September 30th. They set a positive rating on the stock. Finally, Zacks Investment Research raised OpGen from a sell rating to a hold rating in a research note on Wednesday, October 20th.

Shares of NASDAQ OPGN opened at $0.98 on Wednesday. The business’s 50 day moving average is $1.31 and its two-hundred day moving average is $2.11. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.55 and a quick ratio of 1.48. OpGen has a 1-year low of $0.96 and a 1-year high of $4.37.

OpGen (NASDAQ:OPGN) last issued its quarterly earnings data on Thursday, November 11th. The medical research company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. OpGen had a negative return on equity of 82.94% and a negative net margin of 829.32%. The company had revenue of $1.24 million for the quarter, compared to analysts’ expectations of $1.20 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. On average, research analysts predict that OpGen will post -0.79 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP purchased a new stake in OpGen during the third quarter worth $744,000. Geode Capital Management LLC lifted its holdings in shares of OpGen by 64.3% during the 2nd quarter. Geode Capital Management LLC now owns 320,333 shares of the medical research company’s stock valued at $727,000 after purchasing an additional 125,309 shares during the last quarter. State Street Corp purchased a new stake in shares of OpGen during the 2nd quarter valued at $229,000. Vanguard Group Inc. increased its position in shares of OpGen by 7.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,381,207 shares of the medical research company’s stock valued at $3,136,000 after acquiring an additional 91,740 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of OpGen by 502.5% in the 2nd quarter. Renaissance Technologies LLC now owns 86,753 shares of the medical research company’s stock valued at $197,000 after acquiring an additional 72,353 shares during the period. Hedge funds and other institutional investors own 7.52% of the company’s stock.

About OpGen

OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs).

Further Reading: Golden Cross

The Fly logo

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.